Clinical Trial Update: HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC

View source ↗

Summary

Clinical trial update on the HDE use protocol of TheraSphere for unresectable hepatocellular carcinoma has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Hepatocellular Carcinoma | Status: COMPLETED | Results posted: 2015-02-16